ArticleThe Lancet regional health. Europe2024
Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study.
Article in The Lancet regional health. Europe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis.Cardiovascular drugs and therapy · 2026Pooled it
- Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism.The Journal of clinical endocrinology and metabolism · 2026Trial
- Association Between Delayed Metabolic and Bariatric Surgery Completion and Postoperative Cardiometabolic Outcomes.Obesity surgery · 2026Article
- Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Incremental Predictive Value of the Non-HDL-C/HDL-C Ratio for Cryptogenic Stroke in Patients with Patent Foramen Ovale.Journal of cardiovascular development and disease · 2026Article
- Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.European heart journal · 2026Article
- Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease.Current cardiology reports · 2026Review
- Declining eGFR and Uremia Are Associated with Remnant Cholesterol Accumulation and Reduced HDL-C in Non-Dialysis Chronic Kidney Disease.Journal of clinical medicine · 2026Article
- Importance and Management of Non-High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment.JACC. Asia · 2026Review
- Lipid-based atherogenic indices and their relationship with cardiovascular disease risk in an African population of type 2 diabetes mellitus patients.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Genetic insights into coronary heart disease in the Teochew population: Bridging gaps in precision medicine.World journal of cardiology · 2026Article
- Article
- Nonlinear and Age-Specific Associations Between Atherogenic Index of Plasma and Differential Cardiovascular Risk Profiles in US Adults.Cardiovascular therapeutics · 2026Article
- Association of remnant cholesterol with cardiovascular events and mortality in biopsy-proven diabetic kidney disease.Frontiers in endocrinology · 2026Article
- Combined Impact of Mean and Variability of Non-HDL Cholesterol on Myocardial Infarction in Hemodialysis Patients.Journal of clinical medicine · 2025Article
- Short-term animal product dietary restriction alters metabolic profiles and modulates immune function.Communications medicine · 2025Article
- Age-stratified optimal non-HDL cholesterol and all-cause mortality in a healthy Taiwanese population considering personal risk factors.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Correlation between serum low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and clinical characteristics of patients with coronary heart disease: a cross-sectional study.Journal of thoracic disease · 2025Article
- Integrating Emotional Stress and Lipid Lowering in Cardiovascular Disease Management: The Future of Precision Cardiovascular Prevention.Journal of clinical medicine · 2025Article
- Improving cardiovascular risk stratification: the role of abdominal obesity in predicting MACEs.Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Identifying patients at high residual risk of atherosclerotic cardiovascular disease (ASCVD) despite statin-treatment is of paramount clinical importance. We aim to investigate if non-high-density lipoprotein cholesterol (non-HDL-C) identifies residual risk of ASCVD and death in statin-treated patients with ischemic heart disease and low-density lipoprotein cholesterol (LDL-C) ≤ 1.8 mmol/L. Methods: Leveraging Danish regional and national registries, we identified statin-treated patients with ischemic heart disease who underwent coronary angiography (CAG) and attained LDL-C ≤ 1.8 mmol/L within a year post-CAG. Outcomes were myocardial infarction (MI), ASCVD (MI or ischemic stroke), and all-cause death occurring from one year after CAG to end of follow-up. Cox regression analyses obtained adjusted hazard ratios (HR). Findings: Between January 1, 2011, and December 31, 2020, we included 23,641 statin-treated patients with ischemic heart disease and LDL-C ≤ 1.8 mmol/L. During median follow-up of 4.1 years (IQR 2.4-6.1), 893 (3.8%) patients developed MI, 1207 (5.1%) ASCVD, and 3054 (12.9%) patients died. For ASCVD the adjusted HRs (95% confidence interval) for non-HDL-C < 25th percentile (<1.7 mmol/L) versus 25th-74th (1.7-2.1 mmol/L), 75th-94th (2.2-2.6 mmol/L), and ≥95th (≥2.7 mmol/L) percentile were 1.1 (0.9-1.3), 1.4 (1.1-1.7), and 1.8 (1.4-2.4), and for all-cause death 1.0 (0.9-1.1), 1.2 (1.1-1.4), and 1.4 (1.2-1.7), respectively. Interpretation: In a contemporary secondary prevention cohort of patients with well-managed LDL-C, non-HDL-C emerges as an easily accessible marker to detect patients facing high residual risk of ASCVD and death. These findings are important for preventive strategies extending beyond LDL-C targets. Funding: Research grant from the Novo Nordisk Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.